+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

2019 Future of Interstitial Cystitis R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

  • PDF Icon


  • 50 Pages
  • February 2019
  • Region: Global
  • VPA Research
  • ID: 4749287
The global demand for Interstitial Cystitis treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Interstitial Cystitis pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Interstitial Cystitis pipeline companies from advancing their products into Phase 3 or Phase 4.

Interstitial Cystitis Report Description

The 2019 pipeline study on Interstitial Cystitis pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Interstitial Cystitis pipeline compounds.

The Interstitial Cystitis pipeline guide presents information on all active drugs currently being developed for Interstitial Cystitis. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Interstitial Cystitis pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Interstitial Cystitis drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Interstitial Cystitis product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Interstitial Cystitis pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Interstitial Cystitis pipeline report includes
  • An overview of Interstitial Cystitis disease including symptoms, causes, diagnosis and available treatment options is provided.

  • Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

  • Phase wise count of Interstitial Cystitis pipeline

  • Company wise list of Interstitial Cystitis pipeline

  • Mechanism of Action wise Interstitial Cystitis pipeline

For each pipeline candidate, the following details are provided:
  • Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

  • Current status of development

  • Drug overview

  • Mechanism of Action

  • Pre-clinical and Clinical Trials/Results

  • Company Overview and Recent Developments

Reasons to Buy
  • The report is designed to help industry executives promote the success and continued growth of their organizations

  • Get clear understanding of the entire Interstitial Cystitis pipeline, with details on active projects

  • Stay ahead of the competition through comprehensive knowledge of Interstitial Cystitis pipeline progress

  • Get in detail information of each product with updated information on each project along with key milestones

  • Gain clear insights into companies participating in Interstitial Cystitis pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

  • Get trial information for each pipeline product under development

  • Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Table of Contents

1.1 List of Tables

1.2 List of Figures

2. Global Interstitial Cystitis Pipeline Overview
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology

3. Executive Summary
3.1 Interstitial Cystitis Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase 1
3.2.4Phase 2
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase 3
3.3.2 Pre-registration
3.4 Companies involved in Interstitial Cystitis pipeline, H1- 2019
3.5 Mechanism of Action wise Interstitial Cystitis Pipeline Candidates

4 Alivio Therapeutics Inc Interstitial Cystitis Pipeline Details
4.1 Alivio Therapeutics Inc Business Profile
4.2 Alivio Therapeutics Inc Interstitial Cystitis Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5 Astellas Pharma Inc Interstitial Cystitis Pipeline Details
5.1 Astellas Pharma Inc Business Profile
5.2 Astellas Pharma Inc Interstitial Cystitis Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6 GlycoMira Therapeutics Inc Interstitial Cystitis Pipeline Details
6.1 GlycoMira Therapeutics Inc Business Profile
6.2 GlycoMira Therapeutics Inc Interstitial Cystitis Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7 Idera Pharmaceuticals Inc Interstitial Cystitis Pipeline Details
7.1 Idera Pharmaceuticals Inc Business Profile
7.2 Idera Pharmaceuticals Inc Interstitial Cystitis Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8 Kyorin Pharmaceutical Co Ltd Interstitial Cystitis Pipeline Details
8.1 Kyorin Pharmaceutical Co Ltd Business Profile
8.2 Kyorin Pharmaceutical Co Ltd Interstitial Cystitis Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9 Lipella Pharmaceuticals Inc Interstitial Cystitis Pipeline Details
9.1 Lipella Pharmaceuticals Inc Business Profile
9.2 Lipella Pharmaceuticals Inc Interstitial Cystitis Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10 Mirae Cell Bio Co Ltd Interstitial Cystitis Pipeline Details
10.1 Mirae Cell Bio Co Ltd Business Profile
10.2 Mirae Cell Bio Co Ltd Interstitial Cystitis Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11 Pierre Fabre Pharmaceuticals Inc Interstitial Cystitis Pipeline Details
11.1 Pierre Fabre Pharmaceuticals Inc Business Profile
11.2 Pierre Fabre Pharmaceuticals Inc Interstitial Cystitis Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments

12 UCB SA Interstitial Cystitis Pipeline Details
12.1 UCB SA Business Profile
12.2 UCB SA Interstitial Cystitis Drug Details
12.3 Drug Snapshot
12.3.1 Originator
12.3.2 Collaborator/Co-Developer
12.3.3 Route of Administration
12.3.4 Orphan Drug/Fast Track/Special Designation
12.3.5 Geography
12.3.6 Type of Molecular Entity
12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments

13 Urigen Pharmaceuticals Inc Interstitial Cystitis Pipeline Details
13.1 Urigen Pharmaceuticals Inc Business Profile
13.2 Urigen Pharmaceuticals Inc Interstitial Cystitis Drug Details
13.3 Drug Snapshot
13.3.1 Originator
13.3.2 Collaborator/Co-Developer
13.3.3 Route of Administration
13.3.4 Orphan Drug/Fast Track/Special Designation
13.3.5 Geography
13.3.6 Type of Molecular Entity
13.3.7 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments

14 Xigen SA Interstitial Cystitis Pipeline Details
14.1 Xigen SA Business Profile
14.2 Xigen SA Interstitial Cystitis Drug Details
14.3 Drug Snapshot
14.3.1 Originator
14.3.2 Collaborator/Co-Developer
14.3.3 Route of Administration
14.3.4 Orphan Drug/Fast Track/Special Designation
14.3.5 Geography
14.3.6 Type of Molecular Entity
14.3.7 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments

15. Latest Interstitial Cystitis Drug Pipeline Developments, 2019

16. Appendix
16.1 About Us
16.2 Sources and Methodology
16.3 Contact Information

Companies Mentioned

  • Alivio Therapeutics Inc

  • Astellas Pharma Inc

  • GlycoMira Therapeutics Inc

  • Idera Pharmaceuticals Inc

  • Kyorin Pharmaceutical Co Ltd

  • Lipella Pharmaceuticals Inc

  • Mirae Cell Bio Co Ltd

  • Pierre Fabre Pharmaceuticals Inc

  • UCB SA

  • Urigen Pharmaceuticals Inc

  • Xigen SA